No Data
No Data
GLP-1 Obesity Drug Coverage Dropped by Blue Cross Michigan: Report
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Press Release: Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares SAN FRANCISCO, June 07, 2024 (GLOBE
Structure Therapeutics Is Maintained at Outperform by BMO Capital
Structure Therapeutics Is Maintained at Outperform by BMO Capital
No Data